Resources Repository
-
ArticleWeb Portal 2017PLOS Collection: Economic Efficiency of HIV Services
In order to maximize the value for money for HIV services and increase efficiency without …
In order to maximize the value for money for HIV services and increase efficiency without sacrificing quality, robust and up-to-date data on costs, efficiency and its determinants are needed. This PLOS collection, Economic Efficiency of HIV Services, presents recent, high-quality evidence from low- and middle-income countries on costs and technical efficiency of HIV services and their determinants. These data contribute to the current discussion on optimizing resources for HIV services and can provide programmatic guidance for…
Operations Research | Cost-Effectiveness Analysis | Economics/Finance | Asia & Pacific | Middle East & North Africa | Priority Setting/Ethics | Costing Methods | Infectious Diseases | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Test Performance | Technology Assessment | Cost-Effectiveness Analysis | Decision Analysis | Economics/Finance | North America | Costing Methods | Health Outcomes | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Government/Law | Health/Medicine | Science/Technology -
OrganizationWeb Portal 2024Council of Economic Advisers
The Council of Economic Advisers is an agency within the Executive Office of the President …
The Council of Economic Advisers is an agency within the Executive Office of the President and is charged with offering the President objective economic advice on the formulation of both domestic and international economic policy. The Council bases its recommendations and analysis on economic research and empirical evidence, using the best data available to support the President in setting our nation's economic policy. Learn about recent news and reports.
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Risk Analysis | Economics/Finance | North America | Evidence Synthesis | Policy/Regulation | Government/Law -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Benefit-Cost Analysis | Cost-Effectiveness Analysis | Economics/Finance | North America | Priority Setting/Ethics | Infectious Diseases | Policy/Regulation | Health/Medicine | Global -
ArticlePublication 2018Equity Impact Vaccines May Have on Averting Deaths and Medical Impoverishment
In this analysis, authors estimated the number of deaths averted and the number of cases …
In this analysis, authors estimated the number of deaths averted and the number of cases of medical impoverishment averted of ten antigens and their corresponding vaccines across income quintiles for forty-one low- and middle-income countries. The study found that vaccines administered between 2016 and 2030 would prevent 36 million deaths. Vaccines will have the greatest impact on reducing cases of poverty caused by hepatitis B, helping an estimated 14 million people avoid medical impoverishment. An…
Cost-Effectiveness Analysis | Economics/Finance | Asia & Pacific | Middle East & North Africa | Priority Setting/Ethics | Costing Methods | Health Outcomes | Mathematical Models | Infectious Diseases | Child/Nutrition | Global Governance | Health/Medicine | Science/Technology | Sub-Saharan Africa -
ArticleWeb Portal 2017PLoS Collection: Prevention, Diagnosis and Treatment of Sexually Transmitted Infections
Globally, the World Health Organization (WHO) estimates that more than one million new sexually transmitted …
Globally, the World Health Organization (WHO) estimates that more than one million new sexually transmitted infections (STIs) occur each day, incurring a very substantial burden of morbidity, mortality and additional infections. The pathogens responsible include bacteria, parasites and viruses, and intensive research is needed to address the substantial barriers to diagnosis and treatment of STIs, and the behavioral challenges of prevention. This PLOS collection, published in collaboration with WHO, focuses on global policy and systems…
Cost-Effectiveness Analysis | Economics/Finance | Asia & Pacific | Middle East & North Africa | Priority Setting/Ethics | Costing Methods | Mathematical Models | Dynamic Transmission | Infectious Diseases | Health Systems | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
Test Performance | Cost-Effectiveness Analysis | Economics/Finance | North America | State-Transition | Microsimulation | Infectious Diseases | Chronic Disease/Risk | Health Systems | Health/Medicine | Global -
ArticlePublication 2017Getting it Right When Budgets are Tight: Prioritizing Responses to HIV Epidemics
Prioritizing investments across health interventions is complicated by the nonlinear relationship between intervention coverage and …
Prioritizing investments across health interventions is complicated by the nonlinear relationship between intervention coverage and epidemiological outcomes. It can be difficult for countries to know which interventions to prioritize for greatest epidemiological impact, particularly when budgets are uncertain.The authors examined four case studies of HIV epidemics in diverse settings, each with different characteristics. These case studies were based on public data available for Belarus, Peru, Togo, and Myanmar. The Optima HIV model and software package…
Cost-Effectiveness Analysis | Economics/Finance | Asia & Pacific | Middle East & North Africa | Priority Setting/Ethics | Costing Methods | Mathematical Models | Infectious Diseases | Health Systems | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean -
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Cost-Effectiveness Analysis | Economics/Finance | Asia & Pacific | Middle East & North Africa | Health Outcomes | State-Transition | Dynamic Transmission | Microsimulation | Infectious Diseases | Child/Nutrition | Health Systems | Health/Medicine | Sub-Saharan Africa | Latin America & Caribbean